Ensysce Biosciences, Inc. (ENSC)の価格はいくらですか

Ensysce Biosciences, Inc. (ENSC)の価格は$0.2483です

Ensysce Biosciences, Inc. (ENSC)の時価総額は何ですか

Ensysce Biosciences, Inc. (ENSC)の時価総額は$2.30Mです

Ensysce Biosciences, Inc. (ENSC) の利益

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management. Another product, PF614-MPAR, is a combination of PF614 and nafamostat, in Phase I clinical development to provide overdose protection against excessive oral consumption. Furthermore, the company is exploring an oral and inhaled formulation of nafamostat for potential use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. The company's development efforts also include PF329, an extended-release hydromorphone prodrug similar to PF614. In the area of ADHD treatment, Ensysce is advancing PF8001 and PF8026, which are extended-release and immediate-release amphetamine prodrugs, respectively, aimed at deterring medication abuse. Additionally, PF26810, an extended-release methadone prodrug, is in development for opioid use disorder. Ensysce Biosciences, Inc. operates from its headquarters in La Jolla, California.

年	利益	変化
2026 (TTM)	$-12.62M	58.06%
2024	$-7.99M	-24.84%
2023	$-10.63M	-56.10%
2022	$-24.21M	-16.94%
2021	$-29.15M	18,017.11%
2020	$-160.88K	-98.41%
2019	$-10.10M	-477.51%
2018	$2.68M	-9,810.43%
2017	$-27.56K	0.00%

年

利益

変化

2026 (TTM)

$-12.62M

58.06%

2024

$-7.99M

-24.84%

2023

$-10.63M

-56.10%

2022

$-24.21M

-16.94%

2021

$-29.15M

18,017.11%

2020

$-160.88K

-98.41%

2019

$-10.10M

-477.51%

2018

$2.68M

-9,810.43%

2017

$-27.56K

0.00%

企業	利益	利益の差	国
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-41,883.41%	US
Moderna, Inc. MRNA.US	$-3.09B	24,352.67%	US
Argenx SE ARGX.US	$1.95B	-15,551.44%	NL
CSL Limited CSL.AX	$-4.02B	31,713.00%	AU
Lonza Group AG LONN.SW	-	-	CH

企業

利益

利益の差

国